Caribou Biosciences (CRBU) Return on Capital Employed (2021 - 2026)
Caribou Biosciences (CRBU) reported Return on Capital Employed of 92.42% for Q1 2026, down 3071.0% year-over-year from 3.11% in Q1 2025, and little changed on a QoQ basis from 92.85% in Q4 2025.
Caribou Biosciences (CRBU) has 6 years of Return on Capital Employed data on file, last reported at 92.42% in Q1 2026.
- Quarterly Return on Capital Employed fell 3071.0% year-over-year to 92.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 92.42% (down 3071.0% YoY) and the FY2025 annual result came in at 67.76%, down 1906.0% from the prior year.
- Return on Capital Employed held at 92.42% in Q1 2026 per CRBU's latest filing, from 92.85% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18.16% in Q1 2022 and bottomed at 92.85% in Q4 2025.
- The 5-year median for Return on Capital Employed is 38.54% (2023), against an average of 48.03%.
- The widest annual swing landed in 2023, when Return on Capital Employed jumped 185 bps; it then tumbled 3766 bps in 2025.
- Tracing CRBU's Return on Capital Employed over 5 years: stood at 29.71% in 2022, then grew by 6 bps to 27.86% in 2023, then tumbled by 101 bps to 55.88% in 2024, then plunged by 66 bps to 92.85% in 2025, then climbed by 0 bps to 92.42% in 2026.
- Per Business Quant, the three latest CRBU Return on Capital Employed figures stand at 92.42% (Q1 2026), 92.85% (Q4 2025), and 88.26% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -92.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.42% |
| Dec 31, 2025 | -92.85% |
| Sep 30, 2025 | -88.26% |
| Jun 30, 2025 | -76.74% |
| Mar 31, 2025 | -61.71% |
| Dec 31, 2024 | -55.88% |
| Sep 30, 2024 | -50.60% |
| Jun 30, 2024 | -39.44% |
| Mar 31, 2024 | -33.53% |
| Dec 31, 2023 | -27.86% |
| Sep 30, 2023 | -28.81% |
| Jun 30, 2023 | -38.54% |
| Mar 31, 2023 | -34.98% |
| Dec 31, 2022 | -29.71% |
| Sep 30, 2022 | -25.24% |
| Jun 30, 2022 | -21.81% |
| Mar 31, 2022 | -18.16% |
| Dec 31, 2021 | -15.99% |
| Sep 30, 2021 | -22.17% |